Summer 2027
Vendor Management Intern
Summer 2027
Posted on 8/21/2026
Medpace
5,001-10,000 employees
Global CRO delivering full-service clinical trials
No salary listed
Cincinnati, OH, USA
In Person
Full-time, office-based work in the Cincinnati office from May through August 2027.
Bachelor's
 Operations & Logistics (1) |
|---|
Get referred to Medpace
See people who can refer or advise you
- Currently pursuing a Bachelor's degree in Finance, Accounting, Supply Chain Management, Operations Management, Economics, Business Administration, or a similar major.
- Ability to learn GxP regulations and guidelines.
- Ability to organize and multitask while efficiently completing high-quality work.
- Strong analytical and communication skills.
- Ability to work full-time in the Cincinnati office from May through August 2027.
- Learn the service categories that support clinical research by supporting the management of Medpace's vendor relationships and contracts.
- Support the advancement of Vendor Management at Medpace by building new and optimized processes for vendor identification, vendor selection (sourcing), contract execution, performance management, and termination.
- Assist in reviewing third-party quotations, contracts, and amendments while building expertise in request-for-proposal analysis and negotiations.
- Develop an understanding of vendor policies and procedures, including sourcing and purchase contracts.
- Provide support to Vendor Managers in commercial negotiations for pricing and terms.
- Use governance, risk, and compliance software to manage vendor contract execution and performance management.
- Support new vendor due diligence by partnering across Medpace to ensure risk assessment, audit, and vendor compliance processes are followed.
- Monitor third-party vendor performance by leveraging Medpace processes for evaluation and escalation.
- Perform other projects and responsibilities as assigned.
Medpace is a global Contract Research Organization that provides end-to-end clinical development services for pharmaceutical, biotechnology, and medical device leaders. It runs Phase I–IV trials from study design through regulatory submissions, monitoring, data management, statistics, medical writing, and final reporting. A unique feature is ownership of integrated laboratories—global central labs, a bioanalytical lab, and imaging/ECG core labs—that streamline workflows and ensure data consistency. Its goal is to help sponsors bring therapies to market efficiently by coordinating all trial activities under a physician-led, scientifically driven team.
Company Size
5,001-10,000
Company Stage
IPO
Headquarters
Cincinnati, Ohio
Founded
1992
Get referred to Medpace
See people who can refer or advise you
Simplify's Take
What believers are saying
- July 2026 guidance rose to $2.805-$2.885 billion, signaling stronger second-half demand.
- Q2 2026 net new business awards climbed 28.2% to $795.7 million.
- Turtle Creek bought MEDP in Q1 2026, validating cash generation and founder-led discipline.
What critics are saying
- June 2026 securities class action targets February 9 book-to-bill disclosures and management credibility.
- Backlog cancellations can compress bookings fast; February 2026 stock fell 15.9% after guidance miss.
- If biotech funding weakens, Medpace's small- and mid-cap sponsor concentration hits revenue quickly.
What makes Medpace unique
- Physician-led full-service CRO with integrated labs and cross-functional teams across 40-plus countries.
- July 2026 Q2 revenue reached $707.3 million, proving elite execution at scale.
- May 2026 medical hires like Dr. Jack Bleesing deepen rare-disease and cell-therapy expertise.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Flexible Work Hours
Unlimited Paid Time Off
Competitive Compensation and Benefits Package
Employee Health and Wellness Initiatives
Hybrid Work Options
Structured Career Paths with Opportunities for Professional Growth
Growth & Insights and Company News
6 month growth
↑ 11%1 year growth
↑ 11%2 year growth
↑ 11%Medpace reported revenues of $707.3 million in Q2, up 17.2% year on year, exceeding analyst expectations by 2.6%. The contract research organisation, which provides outsourced clinical trial management services to pharmaceutical and biotech companies, achieved the fastest revenue growth among eight drug development inputs and services stocks tracked. The company's full-year revenue guidance surpassed analyst expectations. The sector overall performed strongly, with revenues beating consensus estimates by 4.1% and share prices rising 10.5% on average since earnings. Medpace's stock rose 10.2% following the results and currently trades at $582.23. The drug development inputs and services industry benefits from stable demand as pharmaceutical companies outsource non-core functions through medium to long-term contracts.
Medpace reported second-quarter revenue of $707.3 million, exceeding analyst estimates of $689.7 million and marking 17.2% year-on-year growth. The clinical research company's GAAP profit of $4.25 per share beat consensus estimates by 6.6%. The company raised its full-year revenue guidance to $2.85 billion at the midpoint, up from $2.81 billion previously. Full-year EPS guidance of $17.60 at the midpoint came in 3.9% above analyst expectations. Medpace's stock jumped 18.6% following the results. The company's adjusted EBITDA of $153.4 million also exceeded estimates, delivering a 21.7% margin. Despite the strong performance, analysts expect revenue to remain flat over the next 12 months, suggesting potential demand challenges ahead.
Clinical research company Medpace Holdings will report its second-quarter earnings on Wednesday after market hours. The market expects Medpace's revenue to grow 14.3% year on year this quarter, in line with the 14.2% increase it recorded in the same quarter last year. In the previous quarter, Medpace reported revenues of $706.6 million, up 26.5% year on year, beating analysts' expectations. The company also exceeded EPS estimates, though its full-year EPS guidance aligned with analysts' forecasts. Analysts covering the company have generally reconfirmed their estimates over the last 30 days. Medpace shares have risen 15.8% over the past month, outperforming the life sciences tools and services segment average of 9.9%.
Turtle Creek Asset Management added Medpace Holdings, Inc. (NASDAQ:MEDP) to its portfolio in Q1 2026, citing the clinical research organisation's differentiated strategy. The company focuses on small and mid-sized biopharma companies with full-service offerings, whilst competitors mainly serve Big Pharma with lower-margin work. Medpace's clinician-led model employs full-time MDs and PhDs to develop expertise in complex therapeutic areas. The founder-run company has demonstrated strong growth and cash flow generation. Its capital allocation approach is notably opportunistic, accumulating cash when shares are expensive and repurchasing aggressively when undervalued—buying back nearly 10% of outstanding shares last year. In Q1 2026, Medpace reported revenue of $706.6 million, up 26.5% year-over-year. Shares closed at $475.07, with a market capitalisation of $13.05 billion.
Medpace Hiring 2026: Junior Data Engineer | Apply now. Medpace Hiring 2026: Medpace is hiring Junior Data Engineers in Bengaluru (2026). Apply for an entry-level Data Engineer role - ideal for freshers and early-career professionals with SQL, Python, ETL knowledge. Competitive pay, growth path, and hybrid work options. Apply now to start your data engineering career. About Medpace: Medpace is a scientifically-driven, global, full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services to the biotechnology, pharmaceutical and medical device industries. Medpace's mission is to accelerate the global development of safe and effective medical therapeutics through its high-science and disciplined operating approach that leverages local regulatory and deep therapeutic expertise across all major areas including oncology, cardiology, metabolic disease, endocrinology, central nervous system and anti-viral and anti-infective. Headquartered in Cincinnati, Ohio, Medpace employs approximately 5,800 people across 42 countries. Job description: * Utilize skills in development areas including data warehousing, business intelligence, and databases (Snowflake, ANSI SQL, SQL Server, T-SQL); * Support programming/software development using Extract, Transform, and Load (ETL) and Extract, Load and Transform (ELT) tools, (dbt, Azure Data Factory, SSIS); * Design, develop, enhance and support business intelligence systems primarily using Microsoft Power BI; * Collect, analyze and document user requirements; * Participate in software validation process through development, review, and/or execution of test plan/cases/scripts; * Create software applications by following software development lifecycle process, which includes requirements gathering, design, development, testing, release, and maintenance; * Communicate with team members regarding projects, development, tools, and procedures; and * Provide end-user support including setup, installation, and maintenance for applications. Skills: * Bachelor's Degree in Computer Science, Data Science, or a related field; * Internship experience in Data or Software Engineering; * Knowledge of developing dimensional data models and awareness of the advantages and limitations of Star Schema and Snowflake schema designs; * Solid ETL development, reporting knowledge based off intricate understanding of business process and measures; * Knowledge of Snowflake cloud data warehouse, Fivetran data integration and dbt transformations is preferred; * Knowledge of Python is preferred; * Knowledge of REST API; * Basic knowledge of SQL Server databases is required; * Knowledge of C#, Azure development is a bonus; and * Excellent analytical, written and oral communication skills. Eligibility criteria. * Qualification: B.E / B.Tech * Work Experience: Freshers / Experienced How to apply for Medpace Hiring 2026? Interested candidates can apply online by clicking the application link below: